参考文献/References:
[1] Narayan SM,Cain ME,Smith JM. Atrial fibrillation[J]. Lancet,1997,350(9082):943-950.
[2] Chugh SS,Havmoeller R,Narayanan K,et al. Worldwide epidemiology of atrial fibrillation:a Global Burden of Disease 2010 Study[J]. Circulation,2014,129(8):837-847.
[3] Hindricks G,Potpara T,Dagres N,et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS):the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC[J]. Eur Heart J,2021,42(5):373-498.
[4] Gosselink AT,Crijns HJ,van Gelder IC,et al. Low-dose amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation or flutter[J]. JAMA,1992,267(24):3289-3293.
[5] Tsaban G,Ostrovsky D,Alnsasra H,et al. Amiodarone and pulmonary toxicity in atrial fibrillation:a nationwide Israeli study[J]. Eur Heart J,2024,45(5):379-388.
[6] Christidis G,Lammert F,Krawczyk M. Amiodarone and hypothyroidism[J]. Lancet,2021,397(10275):704.
[7] Bianconi L,Mennuni M,Lukic V,et al. Effects of oral propafenone administration before electrical cardioversion of chronic atrial fibrillation:a placebo-controlled study[J]. J Am Coll Cardiol,1996,28(3):700-706.
[8] Li JX,Wang MQ,Gao M. Remarkably widened QRS complex following a lethal dose of propafenone—An ominous sign[J]. JAMA Intern Med,2022,182(9):990-991.
[9] Andrade JG,Deyell MW,Macle L,et al. Progression of atrial fibrillation after cryoablation or drug therapy[J]. N Engl J Med,2023,388(2):105-116.
[10] Parameswaran R,Al-Kaisey AM,Kalman JM. Catheter ablation for atrial fibrillation:current indications and evolving technologies[J]. Nat Rev Cardiol,2021,18(3):210-225.
[11] Poole JE,Bahnson TD,Monahan KH,et al. Recurrence of atrial fibrillation after catheter ablation or antiarrhythmic drug?therapy in the CABANA trial[J]. J Am Coll Cardiol,2020,75(25):3105-3118.
[12] Kistler PM,Chieng D,Sugumar H,et al. Effect of catheter ablation using pulmonary vein isolation with vs without posterior left atrial wall isolation on atrial arrhythmia recurrence in patients with persistent atrial fibrillation:the CAPLA randomized clinical trial[J]. JAMA,2023,329(2):127-135.
[13] Marrouche NF,Wazni O,Mcgann C,et al. Effect of MRI-guided fibrosis ablation vs conventional catheter ablation on atrial arrhythmia recurrence in patients with persistent atrial fibrillation:the DECAAFⅡ randomized clinical trial[J]. JAMA,2022,327(23):2296-2305.
[14] Verma A,Jiang CY,Betts TR,et al. Approaches to catheter ablation for persistent atrial fibrillation[J]. N Engl J Med,2015,372(19):1812-1822.
[15] Vogler J,Willems S,Sultan A,et al. Pulmonary vein isolation versus defragmentation:the CHASE-AF clinical trial[J]. J Am Coll Cardiol,2015,66(24):2743-2752.
[16] 李艳,秦立,白起君,等. 射频消融术联合抗心律失常药物治疗AF合并HFpEF的效果观察[J]. 临床医学,2023,43(10):63-65.
[17] Tang M,Zhang S,Sun Q,et al. Effect of nifekalant on acute electrical remodelling in rapid atrial pacing canine model[J]. Chin Med J(Engl),2006,119(24):2056-2061.
[18] Hu J,Yu J,Chen Q,et al. Efficacy of nifekalant in patients with Wolff-Parkinson-White syndrome and atrial fibrillation:electrophysiological and clinical findings[J]. J Am Heart Assoc,2019,8(13):e012511.
[19] Isomoto S,Konoe A,Centurion OA,et al. Electrophysiological effects of MS-551 in humans:a classⅢ antiarrhythmic agent[J]. Pacing Clin Electrophysiol,1995,18(11):2022-2027.
[20] Nakaya H,Tohse N,Takeda Y,et al. Effects of MS-551,a new classⅢ antiarrhythmic drug,on action potential and membrane currents in rabbit ventricular myocytes[J]. Br J Pharmacol,1993,109(1):157-163.
[21] Otuki S,Hasegawa K,Watanabe H,et al. The effects of pure potassium channel blocker nifekalant and sodium channel blocker mexiletine on malignant ventricular tachyarrhythmias[J]. J Electrocardiol,2017,50(3):277-281.
[22] Sato R,Koumi S,Hisatome I,et al. A new classⅢ antiarrhythmic drug,MS-551,blocks the inward rectifier potassium channel in isolated guinea pig ventricular myocytes[J]. J Pharmacol Exp Ther,1995,274(1):469-474.
[23] Kondoh K,Hashimoto H,Nishiyama H,et al. Effects of MS-551,a new classⅢ antiarrhythmic drug,on programmed stimulation-induced ventricular arrhythmias,electrophysiology,and hemodynamics in a canine myocardial infarction model[J]. J Cardiovasc Pharmacol,1994,23(4):674-680.
[24] Yamabe H,Tanaka Y,Morihisa K,et al. Electrophysiologic mechanism of typical atrial flutter termination by nifekalant:effect of a pure IKr-selective blocking agent[J]. Pacing Clin Electrophysiol,2013,36(9):1123-1131.
[25] Zhang J,Zan Y,Huo H,et al. Population pharmacokinetic/pharmacodynamic modelling of nifekalant in healthy Chinese volunteers[J]. Eur J Pharm Sci,2020,151:105385.
[26] 加藤貴雄. 日本におけるリドカインと静注Ⅲ 群薬の臨床試験成績（overview）[J]. 心電図 (JPN J Electrocardiology),2009,29(1):3-9.
[27] Tagami T,Matsui H,Ishinokami S,et al. Amiodarone or nifekalant upon hospital arrival for refractory ventricular fibrillation after out-of-hospital cardiac arrest[J]. Resuscitation,2016,109:127-132.
[28] Shiga T,Tanaka K,Kato R,et al. Nifekalant versus lidocaine for in-hospital shock-resistant ventricular fibrillation or tachycardia[J]. Resuscitation,2010,81(1):47-52.
[29] Hayashi M,Tanaka K,Kato T,et al. Enhancing electrical cardioversion and preventing immediate reinitiation of hemodynamically deleterious atrial fibrillation with classⅢ drug pretreatment[J]. J Cardiovasc Electrophysiol,2005,16(7):740-747.
[30] 杜春蕾,郭牧,张云强,等. 尼非卡兰和胺碘酮治疗急性心肌梗死新发房颤有效性和安全性对比研究[J]. 天津医科大学学报,2019,25(05):471-474,480.
[31] 代燕,谢洪祥,阚竞宇,等. 静脉应用尼非卡兰与胺碘酮对阵发性心房颤动患者疗效的比较[J]. 岭南心血管病杂志,2019,25(2):192-194.
[32] 卢冬雪,何琦. 尼非卡兰对阵发性房颤患者转复情况、复律时间及心室率变化的影响[J]. 黑龙江医学,2022,46(14):1704-1706.
[33] 李茹,李华,王焕鹏,等. 尼非卡兰联合厄贝沙坦在阵发性房颤患者中的应用观察[J]. 右江医学,2021,49(6):445-448.
[34] 李凡,夏珍,俞建华,等. 尼非卡兰在心房颤动患者射频消融术后转复的疗效观察[J]. 中华心血管病杂志,2019,47(12):963-968.
[35] Masuda M,Konishi S,Asai M,et al. Usefulness of an IKr blocker for ablation of non-pulmonary vein ectopies that are unmappable due to easily initiated atrial fibrillation[J]. J Interv Card Electrophysiol,2020,58(2):203-208.
[36] 崔海明,汤晔华,万文婷,等. 尼非卡兰与伊布利特转复射频消融术终持续性心房颤动的疗效比较[J]. 中华心律失常学杂志,2019,23(1):39-42.
[37] 陈珊珊,陶四明,杨志刚,等. 尼非卡兰在心房颤动患者射频消融术中转复疗效的观察[J]. 中国心脏起搏与心电生理杂志,2020,34(04):342-344.
[38] Kumagai K,Toyama H. Usefulness of ablation of complex fractionated atrial electrograms using nifekalant in persistent atrial fibrillation[J]. J Cardiol,2013,61(1):44-48.
[39] Zhai Z,Xia Z,Xia Z,et al. Comparison of the efficacy and safety of different doses of nifekalant in the instant cardioversion of persistent atrial fibrillation during radiofrequency ablation[J]. Basic Clin Pharmacol Toxicol,2021,128(3):430-439.
[40] 黄园琴,秦长喻,李颖,等. 盐酸尼非卡兰在瓣膜置换术同期行心房颤动射频消融术后窦性心律的维持作用[J]. 中国心脏起搏与心电生理杂志,2018,32(1):38-40.
相似文献/References:
[1]贺鹏康,周菁.心房颤动治疗新技术——冷冻球囊消融[J].心血管病学进展,2016,(1):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
HE Pengkang,ZHOU Jing.Cryoballoon Ablation, A Novel Technology for Atrial Fibrillation Treatment[J].Advances in Cardiovascular Diseases,2016,(8):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
[2]都明辉,施海峰*,佟佳宾,等.心房颤动消融相关性无症状性脑缺血[J].心血管病学进展,2016,(1):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
DU Minghui,SHI Haifeng*,TONG Jiabin,et al.Silent Cerebral Ischemia Related to Atrial Fibrillation Ablation[J].Advances in Cardiovascular Diseases,2016,(8):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
[3]郑环杰,综述,肖骅,等.心房颤动抗栓治疗研究进展[J].心血管病学进展,2016,(2):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
ZHENG Huanjie,XIAO Hua.Progress of Antithrombotic Therapy in Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(8):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
[4]张清,综述,罗素新,等.新型Xa 因子抑制剂———依度沙班在心房颤动患者抗凝治疗中的研究进展[J].心血管病学进展,2016,(2):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
ZHANG Qing,LUO Suxin,TANG Jiong.Novel Factor Xa Inhibitors—Edoxaban in Prevention of Stroke in
Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(8):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
[5]胡红玲,综述,罗素新,等.预防非瓣膜性心房颤动性脑卒中的治疗新进展[J].心血管病学进展,2016,(3):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
HU Hongling,LUO Suxin.New Progress in the Treatment for Cerebral Apoplexy of Nonvalvular
Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(8):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
[6]王超,杨国澍,综述,等.关附甲素治疗心房颤动的研究进展[J].心血管病学进展,2016,(3):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
WANG Chao,YANG Guoshu,CAI Lin,et al.Research Progress of the Treatment of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(8):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
[7]徐小东,综述,杨东辉,等.决奈达隆治疗心房颤动的现状及展望[J].心血管病学进展,2016,(4):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
XU Xiaodong,YANG Donghui.Status and Prospect of Dronedarone in Treating Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(8):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
[8]张莎,储国俊,吴弘.经导管左心耳封堵术的临床应用进展[J].心血管病学进展,2015,(5):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
ZHANG Sha,CHU Guojun,WU Hong.Clinial Application Advances in Left Atrial Appendage Closure[J].Advances in Cardiovascular Diseases,2015,(8):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
[9]汪俊,杨浩.心房颤动射频消融的术式演变[J].心血管病学进展,2015,(5):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
WANG Jun,YANG Hao.Evolution of Radiofrequency Ablation of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2015,(8):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
[10]赵璐,苏立.心房颤动与离子通道重构研究进展[J].心血管病学进展,2015,(5):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]
ZHAO Lu,SU Li.Research Progress of Atrial Fibrillation and Ion Channel Remodeling[J].Advances in Cardiovascular Diseases,2015,(8):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]